株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

痙攣発作 : パイプライン製品の分析

Seizures - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 257910
出版日 ページ情報 英文 214 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
痙攣発作 : パイプライン製品の分析 Seizures - Pipeline Review, H2 2016
出版日: 2016年07月20日 ページ情報: 英文 214 Pages
概要

痙攣発作は、脳疾患の兆候です。脳内で突然異常な電気的活動が起こることで発生します。症侯としては、目まい、視力変化、胃のむかつき、不安感、コントロールできない筋肉の痙攣などがあります。

当レポートでは、痙攣発作の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲
  • 痙攣発作 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階不明の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • Adamas Pharmaceuticals, Inc.
  • Advicenne
  • Alexza Pharmaceuticals, Inc.
  • Biscayne Pharmaceuticals, Inc.
  • Catalyst Pharmaceuticals, Inc.
  • エーザイ
  • GW Pharmaceuticals Plc
  • INSYS Therapeutics, Inc.
  • Lotus Pharmaceutical Co., Ltd.
  • Marinus Pharmaceuticals, Inc.
  • Neurelis, Inc.
  • Novartis AG
  • OPKO Health, Inc.
  • Pfizer Inc.
  • PTC Therapeutics, Inc.
  • Sage Therapeutics, Inc.
  • SciFluor Life Sciences, LLC
  • Shire Plc
  • SK Biopharmaceuticals Co., Ltd.
  • Suda Ltd
  • Turing Pharmaceuticals AG
  • UCB S.A.
  • Ultragenyx Pharmaceutical Inc.
  • Upsher-Smith Laboratories, Inc.
  • Xenon Pharmaceuticals Inc.
  • XERIS Pharmaceuticals, Inc.
  • Zogenix, Inc.
  • Zynerba Pharmaceuticals, Inc.

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8290IDB

Summary

Global Markets Direct's, 'Seizures - Pipeline Review, H2 2016', provides an overview of the Seizures pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Seizures, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Seizures and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Seizures
  • The report reviews pipeline therapeutics for Seizures by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Seizures therapeutics and enlists all their major and minor projects
  • The report assesses Seizures therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Seizures

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Seizures
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Seizures pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Seizures Overview
  • Therapeutics Development
    • Pipeline Products for Seizures - Overview
    • Pipeline Products for Seizures - Comparative Analysis
  • Seizures - Therapeutics under Development by Companies
  • Seizures - Therapeutics under Investigation by Universities/Institutes
  • Seizures - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Seizures - Products under Development by Companies
  • Seizures - Products under Investigation by Universities/Institutes
  • Seizures - Companies Involved in Therapeutics Development
    • Adamas Pharmaceuticals, Inc.
    • Advicenne
    • Alexza Pharmaceuticals, Inc.
    • Biscayne Pharmaceuticals, Inc.
    • Catalyst Pharmaceuticals, Inc.
    • Eisai Co., Ltd.
    • GW Pharmaceuticals Plc
    • INSYS Therapeutics, Inc.
    • Lotus Pharmaceutical Co., Ltd.
    • Marinus Pharmaceuticals, Inc.
    • Neurelis, Inc.
    • Novartis AG
    • OPKO Health, Inc.
    • Pfizer Inc.
    • PTC Therapeutics, Inc.
    • Sage Therapeutics, Inc.
    • SciFluor Life Sciences, LLC
    • Shire Plc
    • SK Biopharmaceuticals Co., Ltd.
    • Suda Ltd
    • Turing Pharmaceuticals AG
    • UCB S.A.
    • Ultragenyx Pharmaceutical Inc.
    • Upsher-Smith Laboratories, Inc.
    • Xenon Pharmaceuticals Inc.
    • XERIS Pharmaceuticals, Inc.
    • Zogenix, Inc.
    • Zynerba Pharmaceuticals, Inc.
  • Seizures - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ADS-4101 - Drug Profile
    • ADV-6208 - Drug Profile
    • ADV-6770 - Drug Profile
    • alprazolam - Drug Profile
    • AMPX-0079 - Drug Profile
    • ataluren - Drug Profile
    • BIS-001 - Drug Profile
    • brivaracetam - Drug Profile
    • cannabidiol - Drug Profile
    • cannabidiol - Drug Profile
    • CCG-63802 - Drug Profile
    • CHEC-9 - Drug Profile
    • clobazam - Drug Profile
    • CNSA-004 - Drug Profile
    • CPP-115 - Drug Profile
    • CUR-1916 - Drug Profile
    • diazepam - Drug Profile
    • diazepam - Drug Profile
    • everolimus - Drug Profile
    • fenfluramine hydrochloride - Drug Profile
    • fosphenytoin sodium - Drug Profile
    • ganaxolone - Drug Profile
    • lacosamide - Drug Profile
    • levetiracetam - Drug Profile
    • levetiracetam ER - Drug Profile
    • lorazepam - Drug Profile
    • LSPGR-1 - Drug Profile
    • magnesium valproate hydrate - Drug Profile
    • MB-003 - Drug Profile
    • midazolam hydrochloride - Drug Profile
    • midazolam hydrochloride - Drug Profile
    • midazolam hydrochloride - Drug Profile
    • midazolam hydrochloride - Drug Profile
    • Oligonucleotide for Dravet Syndrome - Drug Profile
    • perampanel - Drug Profile
    • pregabalin - Drug Profile
    • SAGE-217 - Drug Profile
    • SAGE-689 - Drug Profile
    • selurampanel - Drug Profile
    • sepranolone - Drug Profile
    • SF-0034 - Drug Profile
    • Small Molecule for Stroke and Epilepsy - Drug Profile
    • Small Molecule to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile
    • Small Molecule to Block Nav1.6 for Dravet Syndrome - Drug Profile
    • Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus - Drug Profile
    • Small Molecules for Seizure Disorders - Drug Profile
    • Small Molecules for Seizures - Drug Profile
    • TG-4155 - Drug Profile
    • TRP-001 - Drug Profile
    • TUR-004 - Drug Profile
    • TUR-005 - Drug Profile
    • UX-007 - Drug Profile
    • YKP-3089 - Drug Profile
    • ZYN-002 - Drug Profile
  • Seizures - Dormant Projects
  • Seizures - Discontinued Products
  • Seizures - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Seizures, H2 2016
  • Number of Products under Development for Seizures - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Seizures - Pipeline by Adamas Pharmaceuticals, Inc., H2 2016
  • Seizures - Pipeline by Advicenne, H2 2016
  • Seizures - Pipeline by Alexza Pharmaceuticals, Inc., H2 2016
  • Seizures - Pipeline by Biscayne Pharmaceuticals, Inc., H2 2016
  • Seizures - Pipeline by Catalyst Pharmaceuticals, Inc., H2 2016
  • Seizures - Pipeline by Eisai Co., Ltd., H2 2016
  • Seizures - Pipeline by GW Pharmaceuticals Plc, H2 2016
  • Seizures - Pipeline by INSYS Therapeutics, Inc., H2 2016
  • Seizures - Pipeline by Lotus Pharmaceutical Co., Ltd., H2 2016
  • Seizures - Pipeline by Marinus Pharmaceuticals, Inc., H2 2016
  • Seizures - Pipeline by Neurelis, Inc., H2 2016
  • Seizures - Pipeline by Novartis AG, H2 2016
  • Seizures - Pipeline by OPKO Health, Inc., H2 2016
  • Seizures - Pipeline by Pfizer Inc., H2 2016
  • Seizures - Pipeline by PTC Therapeutics, Inc., H2 2016
  • Seizures - Pipeline by Sage Therapeutics, Inc., H2 2016
  • Seizures - Pipeline by SciFluor Life Sciences, LLC, H2 2016
  • Seizures - Pipeline by Shire Plc, H2 2016
  • Seizures - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016
  • Seizures - Pipeline by Suda Ltd, H2 2016
  • Seizures - Pipeline by Turing Pharmaceuticals AG , H2 2016
  • Seizures - Pipeline by UCB S.A., H2 2016
  • Seizures - Pipeline by Ultragenyx Pharmaceutical Inc., H2 2016
  • Seizures - Pipeline by Upsher-Smith Laboratories, Inc., H2 2016
  • Seizures - Pipeline by Xenon Pharmaceuticals Inc., H2 2016
  • Seizures - Pipeline by XERIS Pharmaceuticals, Inc., H2 2016
  • Seizures - Pipeline by Zogenix, Inc., H2 2016
  • Seizures - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Seizures - Dormant Projects, H2 2016
  • Seizures - Dormant Projects (Contd..1), H2 2016
  • Seizures - Dormant Projects (Contd..2), H2 2016
  • Seizures - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Seizures, H2 2016
  • Number of Products under Development for Seizures - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top